Phase II dose-ranging trial of RCH 01, an autologous hair cell product, for androgenetic alopecia.

Trial Profile

Phase II dose-ranging trial of RCH 01, an autologous hair cell product, for androgenetic alopecia.

Planning
Phase of Trial: Phase II

Latest Information Update: 29 Apr 2015

At a glance

  • Drugs RCH 01 (Primary)
  • Indications Male pattern baldness
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Apr 2015 Planned initiation date changed from 1 Dec 2014 to 1 Jun 2015, based on a RepliCel Life Sciences media release.
    • 13 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top